PASITHEA THERAPEUTICS CORP. Increase (Decrease) in Accounts Payable and Accrued Liabilities
PASITHEA THERAPEUTICS CORP. (KTTA) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $706.81 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-14
- PASITHEA THERAPEUTICS CORP. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $348.43K, a 36.33% increase year-over-year.
- PASITHEA THERAPEUTICS CORP. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $358.38K, a 73.93% increase year-over-year.
- PASITHEA THERAPEUTICS CORP. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$206.70K, a 142.76% decline year-over-year.
- PASITHEA THERAPEUTICS CORP. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$243.70K.
- PASITHEA THERAPEUTICS CORP. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $11.23K.
- PASITHEA THERAPEUTICS CORP. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$1.43M, a 233.76% decline from fiscal 2023.
- PASITHEA THERAPEUTICS CORP. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $1.07M, a 43.61% increase from fiscal 2022.
- PASITHEA THERAPEUTICS CORP. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $745.76K, a 69.23% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 8 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $348.43K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $706.81K 10-Q · filed 2026-08-14 | $500.12K derived: sum of 3 quarters · filed 2026-08-14 | $256.42K derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | $358.38K 10-Q · filed 2026-05-15 | $151.68K derived: sum of 2 quarters · filed 2026-05-15 | -$92.02K derived: sum of 3 quarters · filed 2026-05-15 | $163.56K derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-12-31 | -$206.70K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$450.40K derived: sum of 2 quarters · filed 2026-03-30 | -$194.82K derived: sum of 3 quarters · filed 2026-08-14 | $11.23K 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | -$243.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $11.88K derived: sum of 2 quarters · filed 2026-08-14 | $217.93K 10-Q · filed 2025-11-13 | $701.30K derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-06-30 | $255.58K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $461.63K 10-Q · filed 2026-08-14 | $945.00K derived: sum of 3 quarters · filed 2026-08-14 | $186.65K derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-03-31 | $206.05K 10-Q · filed 2026-05-15 | $689.43K derived: sum of 2 quarters · filed 2026-05-15 | -$68.93K derived: sum of 3 quarters · filed 2026-05-15 | -$1.11M derived: sum of 4 quarters · filed 2026-05-15 | ||||
| 2024-12-31 | $483.37K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$274.98K derived: sum of 2 quarters · filed 2026-03-30 | -$1.31M derived: sum of 3 quarters · filed 2026-03-30 | -$1.43M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | -$758.35K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$1.80M derived: sum of 2 quarters · filed 2025-11-13 | -$1.92M 10-Q · filed 2025-11-13 | -$1.23M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$1.16M 10-Q · filed 2025-08-14 | -$474.61K derived: sum of 3 quarters · filed 2025-08-14 | -$519.94K derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | -$118.37K 10-Q · filed 2025-05-15 | $564.53K derived: sum of 2 quarters · filed 2025-05-15 | $519.20K derived: sum of 3 quarters · filed 2025-05-15 | $986.45K derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $682.90K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $637.56K derived: sum of 2 quarters · filed 2025-03-24 | $1.10M derived: sum of 3 quarters · filed 2025-03-24 | $1.07M 10-K · filed 2025-03-24 | ||||
| 2023-09-30 | -$45.34K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $421.92K derived: sum of 2 quarters · filed 2024-11-13 | $388.06K 10-Q · filed 2024-11-13 | $668.22K derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $467.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $433.40K 10-Q · filed 2024-08-13 | $713.56K derived: sum of 3 quarters · filed 2024-08-13 | $1.12M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | -$33.85K 10-Q · filed 2024-05-14 | $246.30K derived: sum of 2 quarters · filed 2024-05-14 | $651.97K derived: sum of 3 quarters · filed 2024-05-14 | $682.35K derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $280.15K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $685.82K derived: sum of 2 quarters · filed 2024-03-29 | $716.21K derived: sum of 3 quarters · filed 2024-03-29 | $745.76K 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | $405.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $436.05K derived: sum of 2 quarters · filed 2023-11-13 | $465.61K 10-Q · filed 2023-11-13 | $506.43K 10-Q · filed 2022-11-14 | $384.79K derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $30.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $59.94K 10-Q · filed 2023-08-11 | $99.17K 10-Q · filed 2022-08-15 | -$20.88K derived: sum of 3 quarters · filed 2023-08-11 | $52.54K derived: sum of 4 quarters · filed 2023-08-11 | |||
| 2022-03-31 | $29.55K 10-Q · filed 2023-05-12 | -$13.60K 10-Q · filed 2022-05-16 | -$51.26K derived: sum of 2 quarters · filed 2023-05-12 | $22.15K derived: sum of 3 quarters · filed 2023-05-12 | $237.38K derived: sum of 4 quarters · filed 2023-05-12 | |||
| 2021-12-31 | -$80.82K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$7.40K derived: sum of 2 quarters · filed 2022-11-14 | $207.83K derived: sum of 3 quarters · filed 2022-11-14 | $440.68K 10-K · filed 2022-03-30 | ||||
| 2021-09-30 | $73.42K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $288.64K derived: sum of 2 quarters · filed 2022-11-14 | $521.49K 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | $215.23K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $448.08K 10-Q · filed 2022-08-15 | ||||||
| 2021-03-31 | $232.85K 10-Q · filed 2022-05-16 | |||||||
| 2020-12-31 | $6.60K 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Rocket One Inc. (RKTO) | United States | $0.019B |